Establishment of whole-process intelligent pharmaceutical care model for peritoneal dialysis patients
- VernacularTitle:腹膜透析患者全程智慧化药学服务模式的建立
- Author:
Yongfu HANG
1
;
Yan XU
2
;
Xiaohua DAI
3
;
Tiantian WU
4
;
Yinyin DUAN
5
;
Deyu XU
6
;
Kun HU
6
;
Xingxing LIU
7
;
Jianguo ZHU
1
;
Liyan MIAO
1
;
Lin LI
6
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Soochow University，Jiangsu Suzhou 215006，China
2. Dept. of Pharmacy，the Fifth Affiliated Hospital of Zhengzhou University，Zhengzhou 450052，China
3. Dept. of Pharmacy，Zhaoqing First People’s Hospital，Guangdong Zhaoqing 526000，China
4. Dept. of Pharmacy，Zhengzhou Central Hospital Affiliated to Zhengzhou University，Zhengzhou 450007，China
5. Dept. of Pharmacy，the Affiliated Huaian No.1 People’s Hospital，Jiangsu Huaian 223300，China
6. Dept. of Nephrology，the First Affiliated Hospital of Soochow University，Jiangsu Suzhou 215006，China
7. Dept. of Pharmacy，Guiyang Maternal and Child Health Care Hospital，Guiyang 550003，China
- Publication Type:Journal Article
- Keywords:
peritoneal dialysis;
pharmaceutical care;
work
- From:
China Pharmacy
2023;34(21):2644-2648
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To develop a whole-process intelligent model of pharmaceutical care for peritoneal dialysis （PD） patients， and to provide a reference for clinical pharmacists to provide standardized PD pharmaceutical care. METHODS The pharmaceutical care mode of PD patients at home and abroad was investigated and analyzed. Based on the actual situation of the First Affiliated Hospital of Soochow University （hereinafter referred to as “our hospital”）， with “home→PD center outpatient→ inpatient department” as the main node， the recycling process of medication reconciliation was optimized. The whole-process intelligent pharmaceutical care model of PD was illustrated by improving the Chinese version of the drug-related problems （DRPs） classification tool， developing the corresponding pharmaceutical care process， and presenting specific cases. RESULTS Based on the medication therapy management （MTM） platform， our hospital had built a closed-loop PD whole-process intelligent pharmaceutical care model of “in-hospital pharmaceutical care （building document）-PD outpatient MTM-home pharmaceutical care （online App management）”. A “double cycle” workflow of “admission→discharge→outpatient” medication reconciliation cycle and “discovery-analysis-intervention-follow-up-record-evaluation” DRPs cycle was formed. CONCLUSIONS The establishment of the whole-process intelligent pharmaceutical care model for PD in our hospital provides experience for standardizing pharmaceutical care for PD patients， and can reduce DRPs.
